DexTech Medical AB (FRA:LQ0) Ending Cash Position: €0.79 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LQ0 DexTech Medical AB FRA:LQ0
30 GF Score
Price €0.85
! 2 Warning Signs
View Full Analysis

What is DexTech Medical AB Ending Cash Position?

DexTech Medical AB FRA:LQ0 -0.93% 30 Ending Cash Position is €0.79 Mil as of Jun. 2026. GuruFocus rates FRA:LQ0 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

DexTech Medical AB's Ending Cash Position for the quarter that ended in Jun. 2026 was €0.79 Mil.

DexTech Medical AB's quarterly Ending Cash Position declined from Dec. 2025 (€1.12 Mil) to Mar. 2026 (€0.94 Mil) and declined from Mar. 2026 (€0.94 Mil) to Jun. 2026 (€0.79 Mil).

DexTech Medical AB's annual Ending Cash Position declined from Jun. 2024 (€1.69 Mil) to Jun. 2025 (€1.34 Mil) and declined from Jun. 2025 (€1.34 Mil) to Jun. 2026 (€0.79 Mil).

DexTech Medical AB Ending Cash Position Related Terms

DexTech Medical AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Ending Cash Position Chart

DexTech Medical AB Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.34 2.16 1.69 1.34 0.79

DexTech Medical AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.34 1.28 1.12 0.94 0.79
FRA:LQ0
30GF Score
DexTech Medical AB FRA:LQ0
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

DexTech Medical AB's Ending Cash Position for the fiscal year that ended in Jun. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.342+-0.555
=0.79

DexTech Medical AB's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.923+-0.136
=0.79

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.79 Mil mean?
DexTech Medical AB (FRA:LQ0) has a Ending Cash Position of €0.79 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DexTech Medical AB and its competitors.
Is DexTech Medical AB's Ending Cash Position too high?
DexTech Medical AB's current Ending Cash Position is €0.79 Mil. Overall, DexTech Medical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Ending Cash Position compare to VRTX and REGN?
DexTech Medical AB's Ending Cash Position of €0.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on DexTech Medical AB and its competitors. DexTech Medical AB's current Ending Cash Position is €0.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (FRA:LQ0) has a current Ending Cash Position of €0.79 Mil. The current Ending Cash Position is €0.79 Mil. DexTech Medical AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For DexTech Medical AB (FRA:LQ0), the current Ending Cash Position is €0.79 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Other Exchanges DEX:Sweden
Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
30GF Score

Get the complete analysis for FRA:LQ0

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.85
Price